# Study of Verinurad in Heart Failure With Preserved Ejection Fraction

> **NCT04327024** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 159 (actual)

## Conditions studied

- Heart Failure With Preserved Ejection Fraction (HFpEF)

## Interventions

- **DRUG:** Verinurad
- **DRUG:** Allopurinol
- **DRUG:** Placebo for verinurad
- **DRUG:** Placebo for allopurinol

## Key facts

- **NCT ID:** NCT04327024
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-19
- **Primary completion:** 2022-04-29
- **Final completion:** 2022-04-29
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2023-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04327024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04327024, "Study of Verinurad in Heart Failure With Preserved Ejection Fraction". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04327024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*